The wider picture
Psoriasis affects more than 8 million Americans, with nearly one quarter of cases considered moderate-to-severe. Traditionally, patients have relied on topical treatments or injectable therapies, with many not advancing from topicals to shots. The cost of rival injectable treatments, such as Tremfya and Skyrizi, can reach up to $100,000 per year, creating a significant barrier for those seeking effective management of their condition.
In a groundbreaking development, Icotyde has been approved by the FDA as the first oral treatment for moderate to severe plaque psoriasis. This approval marks a significant milestone in the treatment landscape for this chronic skin condition. Icotyde is taken once daily with water, 30 minutes before eating, offering a more convenient option for patients compared to existing therapies.
Developed by Johnson & Johnson and Protagonist Therapeutics, Icotyde targets the IL-23 receptor, a key driver of the inflammatory response in plaque psoriasis. The approval is based on data from the ICONIC clinical development program, which enrolled approximately 2,500 patients. In superiority studies, approximately 70% of patients achieved clear or almost clear skin at week 16, showcasing the treatment’s efficacy.
Jennifer Taubert, a representative from Johnson & Johnson, emphasized the importance of this new treatment, stating, “To be able to have something that is relatively simple, that offers that level of clearance, trusted safety profile, and in a simple pill, we think is going to be revolutionary.” This sentiment reflects the hope that Icotyde will provide a much-needed solution for many patients who struggle with the limitations of current therapies.
Linda Stein Gold, M.D., noted that “Icotyde delivers something unique in psoriasis treatment, combining skin clearance with a favorable safety profile in a once-daily pill, making it an easy addition to a patient’s routine.” This ease of use is particularly significant, as finding the right treatment can often take time and requires consideration of multiple factors, including efficacy, safety, and how the treatment fits into everyday life.
Moreover, Icotyde is not just limited to psoriasis; it is currently being tested for other autoimmune conditions such as psoriatic arthritis, ulcerative colitis, and Crohn’s disease. Analysts predict that Icotyde could exceed $5 billion in peak annual sales once approved for these additional indications, further highlighting its potential impact on the market.
As the approval of Icotyde provides a new systemic treatment option that works differently from existing therapies, it is expected to change the conversation about treatment options within the psoriasis community. Leah M. Howard, J.D., remarked, “The approval of a novel systemic therapy changes the conversation about treatment options for our community.” This reflects a growing recognition of the need for innovative solutions in managing chronic conditions.
With the approval of Icotyde, patients now have a new oral option that could significantly improve their quality of life. As the healthcare community continues to monitor the rollout of this treatment, many are hopeful that it will lead to better outcomes for those affected by psoriasis.